PMID- 22481373
OWN - NLM
STAT- MEDLINE
DCOM- 20121016
LR  - 20211021
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 61
IP  - 7
DP  - 2012 Jul
TI  - Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-kappaB 
      activation in a mouse model of allergic asthma.
PG  - 749-58
LID - 10.1007/s00011-012-0470-6 [doi]
AB  - OBJECTIVE: We investigated whether roxithromycin reduces ovalbumin-specific 
      allergic asthma symptoms in mice, and we further investigated the inhibitory 
      mechanism of roxithromycin in ovalbumin-specific allergic asthma. METHODS: Mice 
      were divided into five groups (n = 10 for each): control group, 
      roxithromycin-treated groups (5, 20 and 40 mg/kg) and ovalbumin-challenged group. 
      We measured the recruitment of inflammatory cells into the bronchoalveolar lavage 
      fluid (BALF) or the lung tissues by Kwik-Diff and hematoxylin and eosin (H&E) 
      staining, goblet cell hyperplasia by alcian blue-periodic acid-Schiff (AB-PAS) 
      staining, airway hyperresponsiveness (AHR) by whole-body plethysmograph chamber, 
      cytokine and immunoglobulin E (IgE) levels by ELISA, and the activation of 
      mitogen-activated protein (MAP) kinases and nuclear factor-kappa B (NF-kappaB) in the 
      lung tissues by Western blotting. RESULTS: Treatment with roxithromycin resulted 
      in fewer inflammatory cells in the BALF and peribronchial areas, and decreased 
      AHR, goblet cell hyperplasia, IgE levels and inflammatory cytokines, as well as 
      MAP kinases and NF-kappaB activation, which are increased in lung tissues of mice 
      with ovalbumin-induced allergic asthma. CONCLUSIONS: Our data suggest that oral 
      administration of roxithromycin suppresses ovalbumin-induced airway inflammation 
      and AHR by regulating the inflammatory cytokines via MAP kinases/NF-kappaB pathway in 
      inflammatory cells. Based on these results, we suggest that roxithromycin may be 
      used as a therapeutic agent for allergy-induced asthma.
FAU - Ci, Xinxin
AU  - Ci X
AD  - Key Laboratory of Zoonosis Research, Institute of Zoonosis, College of Animal 
      Science and Veterinary Medicine, Ministry of Education, Jilin University, 5333 
      Xi'an Road, Changchun 130062, People's Republic of China.
FAU - Chu, Xiao
AU  - Chu X
FAU - Xu, Xue
AU  - Xu X
FAU - Li, Hongyu
AU  - Li H
FAU - Deng, Xuming
AU  - Deng X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120406
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - 21KOF230FA (Roxithromycin)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Allergens/immunology
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Asthma/*drug therapy/immunology/pathology/physiopathology
MH  - Bronchial Hyperreactivity/immunology/pathology/physiopathology
MH  - Bronchoalveolar Lavage Fluid/cytology/immunology
MH  - CD4-Positive T-Lymphocytes/cytology/immunology
MH  - Cell Count
MH  - Cell Differentiation
MH  - Cytokines/immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Immunoglobulin E/blood
MH  - Lung Compliance
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mitogen-Activated Protein Kinases/*immunology
MH  - NF-kappa B/*immunology
MH  - Ovalbumin/immunology
MH  - Roxithromycin/*therapeutic use
EDAT- 2012/04/07 06:00
MHDA- 2012/10/17 06:00
CRDT- 2012/04/07 06:00
PHST- 2011/07/30 00:00 [received]
PHST- 2012/03/15 00:00 [accepted]
PHST- 2012/03/15 00:00 [revised]
PHST- 2012/04/07 06:00 [entrez]
PHST- 2012/04/07 06:00 [pubmed]
PHST- 2012/10/17 06:00 [medline]
AID - 10.1007/s00011-012-0470-6 [doi]
PST - ppublish
SO  - Inflamm Res. 2012 Jul;61(7):749-58. doi: 10.1007/s00011-012-0470-6. Epub 2012 Apr 
      6.